This is a larger dose meant to get enough Dupixent into your system quickly so it can begin working. Your loading dose will be either 400 milligrams (mg) (consisting of two 200-mg injections ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

Bristol Myers Squibb has continued its ruthless cost-cutting push, dropping plans to commercialize a rival to Dupixent despite meeting its phase 3 goals and pumping the brakes on a would-be ...

Despite Eylea's market challenges, Dupixent's strong performance and future potential in COPD, along with a robust pipeline, position Regeneron for recovery in 2025. Regeneron's solid financials ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

One primary reason is the strong performance and potential of Dupixent, which is expected to partially counterbalance the uncertainties surrounding Eylea. The expected growth in Dupixent’s ...

The CEO discussed the success of Dupixent and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and setting a milestone for Sanofi.

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone ...

After all, there are enough tailwinds suggesting that it may be able to regain its mojo once again and even hit the $200 mark. AI infrastructure spending is set to be massive in 2025 Concerns ...

The OPFS estimates a net present value of $2.3-billion, compared with the $2.4-billion estimated in the initial PFS. The project is expected to deliver earnings before interest, taxes ...

Furthermore, the successful launch of Dupixent for chronic obstructive pulmonary disease (COPD) has garnered significant coverage from top commercial and Medicare payers, indicating strong market ...

Midtier gold producer and explorer Gold Road Resources has unveiled the findings of a prefeasibility study (PFS) for its 100%-owned ... that is expected to produce 200 000 oz over a four-year ...